Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116930 · ClinicalTrials.gov registry record · Phase 2
Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture
A Phase 2 study of Post-Dural Puncture Headache, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05116930: Recruiting Phase 2 study of Post-Dural Puncture Headache, sponsored by Mayo Clinic.
NCT05116930 is a Phase 2 study of Post-Dural Puncture Headache that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05116930, a Phase 2 study of Post-Dural Puncture Headache, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.
Primary Outcome
Total number of postpartum women with a post dural puncture headache (PDPH) requiring epidural blood patch (EBP)
Conditions Studied
Interventions
- DRUG Neostigmine
- DRUG Glycopyrrolate
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT05116930 shows while recruiting
NCT05116930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Post-Dural Puncture Headache appearing as the primary indexed condition, and to 2 interventions - of which Neostigmine is the first listed.
NCT05116930 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05116930 about?
NCT05116930 is a clinical study titled "Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture". The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.
What is the current status of trial NCT05116930?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-11-19. Estimated completion is 2027-12.
What conditions does trial NCT05116930 study?
This clinical trial studies the following conditions: Post-Dural Puncture Headache.
What interventions are being tested in trial NCT05116930?
The interventions under investigation include: Neostigmine (DRUG), Glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT05116930?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05116930 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05116930's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI